RBC Capital analyst Deane Dray lowered the firm’s price target on Ametek (AME) to $204 from $210 and keeps an Outperform rating on the shares. The company delivered a mostly in-line Q4 with seasonally solid free cash flows and robust $3.4B, but its 2025 guidance was light, the analyst tells investors in a research note. The company remains optimistic that both headwinds should ease as 2025 progresses however, and given AMETEK’s proven quality compounder model and attractive valuation, RBC remains positive on the stock, the firm added.